Venugopal Considers BTK and BCL2 Inhibitors in Patient With CLL
July 22nd 2021Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.
Tafasitamab/Lenalidomide Combo Demonstrates Favorable Efficacy in DLBCL
July 21st 2021In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.
FDA Approves Belumosudil for Chronic Graft Versus Host Disease
July 16th 2021FDA approval has been granted approval to belumosudil for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.
Roundtable Discussion: Defining How the JAVELIN Trial Changes Practice in Metastatic Bladder Cancer
July 9th 2021During a Targeted Oncology Case-Based Roundtable event, Daniel A. Landau, MD, moderated a discussion around the JAVELIN trial and how its results were practice changing for oncologists treating for bladder cancer.
Roundtable Discussion: Brose Explores Selpercatinib and Pralsetinib in MTC
July 6th 2021Both selpercatinib and pralsetinib are FDA-approved therapies for RET-altered medullary thyroid cancer. The research supporting both agents and the experience with their use in clinical practice was the topic of a recent Case-Based Roundtable event moderated by Marcia S. Brose, MD, PhD.
Roundtable Discussion: Examining MRD as a Prognostic Factor in Transplant-Eligible Multiple Myeloma
July 5th 2021During a Targeted Oncology Case-Based Roundtable event, Olalekan O. Oluwole, MD, MBBS, MPH, leads a discussion around identifying prognostic factors for a patients with transplant-eligible multiple myeloma.
Importance of Achieving MRD Negativity Considered for Transplant-Eligible Multiple Myeloma
June 27th 2021Regarding the case of a 51-year-old man who first presented with pallor and worsening fatigue on exertion and was diagnosed with transplant-eligible multiple myeloma, Rafael Fonseca, MD, discussed available treatment options.
Multiple Agents Prove Useful in RET-Mutated Thyroid Cancer
June 24th 2021Many options are available for the treatment of RET-mutated thyroid cancer. During a Targeted Oncology Case-Based Roundtable event, Francis Paul Worden, MD, discussed the case of a 58-year-old patients who first presented with solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue.
Roundtable Discussion: Fonseca Compares Frontline Therapy in Newly Diagnosed Multiple Myeloma
June 1st 2021Various frontline treatments can be administered to a patient with newly-diagnosed multiple myeloma. Rafael Fonseca, MD, and a group of peers compare the available agents during a Targeted Oncology, Cased- Based Roundtable event.